Bellicum Secures $35M Via Equity Funding, Posts Interim Data From Early GoCAR-T Cancer Studies

Bellicum will issue pre-funded warrants to purchase up to 20.6 million shares and accompanying warrants to purchase up to 2.06 million shares at a combined unit price of $1.7024. Warrants have an exercise price of $1.69 per share.

  • Bellicum Pharmaceuticals Inc BLCM also announced interim data from its ongoing Phase 1/2 GoCAR-T trials.
  • In the first three-patient cohort of metastatic castration-resistant prostate cancer (mCRPC) treated at 5x106 cells/kg BPX-601 followed by single-dose rimiducid, no dose-limiting toxicities were observed. 
  • A confirmed partial response was observed in one patient, accompanied by a substantial reduction in PSA in response to treatment with BPX-601 and rimiducid.
  • Enrollment is ongoing in the second dose cohort in mCRPC of 5x106 cells/kg followed by weekly rimiducid, and results will be submitted at a medical meeting in 2022.
  • Enrollment is ongoing in the Phase 1/2 clinical trial for BPX-603 patients with solid tumors expressing human epidermal growth factor 2 (HER2). 
  • In the first patients treated in this trial at dose level 1 of 0.1x106 cells/kg, BPX-603 alone or followed by weekly rimiducid showed no dose-limiting toxicities.
  • Price Action: BLCM shares are down 11.20% at $1.50 during the market session on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareFinancingOfferingsMoversTrading IdeasGeneralBriefsPhase 1 TrialPhase 2 Trialprostate cancer
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!